Alpha 2.0
Login Register
» Authors » Francois Laliberte

Francois Laliberte

Explore the profile of Francois Laliberte including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 131
Citations 1054
Followers 0
Related Specialties
Pharmacology
Oncology
General Medicine
Top 10 Co-Authors
Patrick Lefebvre
Guillaume Germain
Mei Sheng Duh
Dominique Lejeune
Concetta Crivera
Jeff Schein
Winnie W Nelson
Sean D MacKnight
Veronica Ashton
Dominic Pilon
Published In
J Med Econ
Curr Med Res Opin
Adv Ther
Int J Chron Obstruct Pulmon Dis
Future Oncol
Affiliations
Soon will be listed here.
Recent Articles
11.
Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes
Mannino D, DiRocco K, Germain G, Laliberte F, Noorduyn S, Urosevic A, et al.
Adv Ther . 2024 Oct; 41(12):4557-4580. PMID: 39453592
Introduction: Previous real-world evidence suggests that prompt versus delayed initiation of single-inhaler triple therapy (SITT) with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) following an exacerbation results in improved clinical outcomes for patients with...
12.
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States
Hultcrantz M, Kleinman D, Vij R, Escalante F, Delforge M, Kotowsky N, et al.
Haematologica . 2024 Oct; 110(3):753-757. PMID: 39415693
No abstract available.
13.
Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib
De Nigris E, Yang X, Zanardo E, Lejeune D, Farooqui M, Gandra S, et al.
Future Oncol . 2024 Oct; 20(35):2723-2735. PMID: 39373600
Evaluate healthcare resource utilization (HRU) and costs in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who relapsed or are refractory to (R/R) ibrutinib. All-cause and CLL/SLL-related HRU and healthcare costs...
14.
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count
Germain G, Worley K, MacKnight S, Rubin B, Bell C, Laliberte F, et al.
Lupus Sci Med . 2024 Apr; 11(1). PMID: 38575172
Objective: To investigate the real-world impact of intravenous belimumab treatment among patients with SLE using rheumatoid arthritis-derived disease activity measures and SLE-related laboratory values. Methods: This retrospective cohort study used...
15.
Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma
Casale T, Corbridge T, Germain G, Laliberte F, MacKnight S, Boudreau J, et al.
Allergy Asthma Clin Immunol . 2024 Mar; 20(1):25. PMID: 38532489
Background: Systemic corticosteroid (SCS) use remains widespread among patients with severe asthma, despite associated complications. Objective: Evaluate the association between cumulative SCS exposure and SCS-related complications in severe asthma. Methods:...
16.
Real-world users of triple therapy for asthma in the US
Hansel N, Abbott C, Averell C, Germain G, Laliberte F, Mahendran M, et al.
Am J Manag Care . 2024 Feb; 30(2):74-81. PMID: 38381542
Objectives: For patients with asthma who remain symptomatic on a medium-dose inhaled corticosteroid/long-acting β2 agonist, addition of a long-acting muscarinic antagonist as a supplementary controller is a recommended option. However,...
17.
Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder
Laliberte F, Zanardo E, MacKnight S, Urosevic A, Wade S, Parikh M
J Manag Care Spec Pharm . 2024 Feb; 30(2):118-128. PMID: 38308622
Background: Formulary restrictions, intended to limit inappropriate medication use and decrease pharmacy costs, may prevent or delay patients with bipolar I disorder from initiating cariprazine, a dopamine D-preferring D/D and...
18.
Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US
Yang X, Zanardo E, Lejeune D, De Nigris E, Sarpong E, Farooqui M, et al.
Oncologist . 2024 Jan; 29(3):e360-e371. PMID: 38280190
Background: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia among US adults and has experienced a rapidly evolving treatment landscape; yet current data on treatment patterns in...
19.
Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
Bogart M, Germain G, Laliberte F, Mahendran M, Duh M, DiRocco K, et al.
J Asthma Allergy . 2023 Dec; 16:1309-1322. PMID: 38058516
Purpose: Real-world asthma control data among patients initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are limited. This study assessed rescue medication use and asthma-related exacerbations in patients with asthma before and after initiating...
20.
Real-World Incidence of Adverse Clinical Outcomes Among People With Coronary Artery Disease and/or Peripheral Artery Disease in Relation to Vascular Risk in the United States
Desai U, Babcock A, Wang Y, Akbarnejad H, Lemus Wirtz E, Laliberte F, et al.
Am J Cardiol . 2023 Oct; 208:44-52. PMID: 37812866
Presence of polyvascular disease, diabetes, heart failure, or renal insufficiency in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD) are associated with increased risks of adverse...